AstraZeneca Plc reported a 16% increase in product sales to $6 billion the third quarter and a rise of 13% in the first nine months to $17.3 billion after years of investment in new products lifted it off one of the industry’s biggest patent cliffs. Driving the result were higher sales of the lung cancer drugs Tagrisso and Imfinzi and strong performances by the antiplatelet medicine Brilinta and the respiratory drug Symbicort. Geographically, sales grew strongly in the emerging markets, led by China, followed by Japan and the US.
